BJDX Bluejay Diagnostics, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1704287 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-12.2%
TTM EPS YoY119.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-138.1%
ROA-107.8%
ROIC (approx.)-1,839.1%
Asset turnover—
Leverage & solvency
Liabilities / assets20.6%
Debt / equity0.00x
Current ratio3.91x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-16.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.12M | $1.44M | $811,837 | $586,144 | $785,608 | $889,896 | $784,800 | $553,997 |
| SG&A expense | $944,845 | $911,318 | $1.13M | $875,603 | $831,339 | $1.10M | $1.10M | $929,831 |
| Operating income | -$2.06M | -$2.35M | -$1.94M | -$1.46M | -$1.62M | -$1.99M | -$1.89M | -$1.48M |
| Interest expense | — | — | — | $187 | $200 | $222 | — | $15,231 |
| Net income | -$2.01M | -$2.32M | -$1.92M | -$1.43M | -$1.60M | -$1.96M | -$1.86M | -$1.43M |
| EBITDA | -$2.00M | -$2.32M | -$1.91M | -$1.43M | -$1.61M | -$1.97M | -$1.87M | -$1.46M |
| EPS (basic) | -1.72 | -1.12 | -1.95 | — | -16.92 | -5.64 | -13.46 | — |
| EPS (diluted) | -1.72 | -1.12 | -1.95 | — | -16.92 | -5.64 | -13.46 | — |
| Weighted avg. shares (diluted) | 1.17M | 2.08M | 984,668 | — | 94,408 | 346,780 | 138,503 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $7.38M | $9.60M | $3.68M | $5.16M | $3.08M | $4.44M | $3.12M | $4.30M |
| Current assets | $7.54M | $9.81M | $3.97M | $5.46M | $3.35M | $4.75M | $3.57M | $4.90M |
| PP&E, net | $1.78M | $1.64M | $1.53M | $1.53M | $1.39M | $1.48M | $1.50M | $1.51M |
| Total assets | $9.37M | $11.53M | $5.60M | $7.12M | $4.89M | $6.40M | $5.28M | $6.66M |
| Current liabilities | $1.93M | $2.12M | $1.41M | $1.12M | $1.15M | $1.04M | $1.32M | $810,368 |
| Total liabilities | $1.93M | $2.12M | $1.42M | $1.14M | $1.20M | $1.11M | $1.41M | $927,924 |
| Shareholders' equity | $7.44M | $9.41M | $4.18M | $5.98M | $3.69M | $5.29M | $3.87M | $5.73M |
| Shares outstanding | 1.12M | 1.98M | 1.03M | 151,133 | 1.64M | 1.49M | 554,012 | 138,503 |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.00M | -$1.50M | -$1.59M | -$1.45M | -$1.36M | -$2.05M | -$1.18M | -$1.45M |
| Capital expenditure | $196,818 | $142,773 | $18,989 | — | — | — | — | $1,125 |
| Free cash flow | -$2.20M | -$1.64M | -$1.61M | — | — | — | — | -$1.45M |
| Investing cash flow | -$196,443 | -$142,773 | -$15,314 | — | — | — | — | -$1,125 |
| Financing cash flow | -$19,530 | $7.56M | $124,096 | $3.71M | -$1,015 | $3.38M | -$985 | -$1,326 |
| Depreciation & amortization | $61,922 | $28,193 | $27,763 | $27,415 | $10,624 | $17,742 | $18,401 | $19,775 |
| Stock-based compensation | $55,972 | — | — | $74 | $183 | -$1,563 | $1,312 | -$2,582 |
| Share buybacks | $18,560 | — | — | — | $0 | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.